Immunotherapy for atherosclerosis by targeting proinflammatory T cells  

作　　者：Amir Khan Klaus Ley 

机构地区：[1]Immunology Center of Georgia,Augusta University,Augusta,GA,USA.

出　　处：《Cell Research》2024年第7期467-468,共2页细胞研究（英文版）

摘　　要：Recent advancements in atherosclerosis management have shifted focus beyond lipid-lowering strategies towards addressing residual inflammatory risks associated with major adverse cardiovascular events.In a recent Cell Research paper,Fan et al.reported that anti-PD-1 monoclonal antibody therapy reduces atherosclerosis plaque size and modulates inflammation by serving as a surrogate PD-1 ligand through interaction with myeloid-expressed Fc gamma receptors.Atherosclerosis is a chronic inflammatory disease of the arteries that leads to major adverse cardiovascular events(MACEs)including ischemic heart disease and stroke.1 Despite advancements in lipidlowering therapies,a significant residual risk of MACEs persists,underscoring the need for innovative treatment strategies.1 Recent research has shifted focus to the role of adaptive immunity in atherosclerosis,with T-cells emerging as pivotal players in disease progression.2–4 Immunotherapy has revolutionized oncology and is now set to bring its transformative potential to atherosclerosis management.Studies have demonstrated the intricate dance between lipids and inflammation,hinting at a nuanced interdependency rather than a simple cause-and-effect relationship.For example,the CANTOS trial,which targeted inflammation with the interleukin-1βinhibitor canakinumab.

关 键 词：ATHEROSCLEROSIS INFLAMMATION INFLAMMATORY 

分 类 号：R730.51[医药卫生—肿瘤]